Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00807937
Other study ID # D1140C00014
Secondary ID
Status Completed
Phase Phase 2
First received December 12, 2008
Last updated September 16, 2010
Start date December 2008
Est. completion date May 2009

Study information

Verified date September 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.


Recruitment information / eligibility

Status Completed
Enrollment 369
Est. completion date May 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Signed informed consent before any study-related procedures start.

- The patient is previously diagnosed with Generalized Anxiety Disorder.

- The patient has a HADS-A (anxiety) score =10 at both screening and randomization.

Exclusion Criteria:

- Patient has a lifetime history of schizophrenia or other psychotic disorders

- Patient has a history of seizures or seizure disorder.

- Patient is pregnant or breast feeding.

- Patient has received electroconvulsive treatment (ECT) in the past.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
AZD7325
4 tablets and 1 capsule taken twice a day for 28 days
AZD7325
4 tablets and 1 capsule taken twice a day for 28 days
Lorazepam
4 tablets and 1 capsule taken twice a day for 28 days
Placebo
4 tablets and 1 capsule taken twice a day for 28 days

Locations

Country Name City State
United States Research Site Allentown Pennsylvania
United States Research Site Atlanta Georgia
United States Research Site Austin Texas
United States Research Site Bartlett Tennessee
United States Research Site Braintree Massachusetts
United States Research Site Carson California
United States Research Site Cedarhurst New York
United States Research Site Charleston South Carolina
United States Research Site Cincinnati Ohio
United States Research Site Cleveland Ohio
United States Research Site Dallas Texas
United States Research Site Dayton Ohio
United States Research Site Escondido California
United States Research Site Eugene Oregon
United States Research Site Fort Lauderdale Florida
United States Research Site Fort Myers Florida
United States Research Site Gainsville Florida
United States Research Site Glen Burnie Maryland
United States Research Site Glendale California
United States Research Site Hallandale Beach Florida
United States Research Site Hoffman Estates Illinois
United States Research Site Irvine California
United States Research Site Jacksonville Florida
United States Research Site Lafayette Indiana
United States Research Site Little Rock Arkansas
United States Research Site Maitland Florida
United States Research Site Mesa Arizona
United States Research Site New York New York
United States Research Site Oak Brook Illinois
United States Research Site Oklahoma City Oklahoma
United States Research Site Orlando Florida
United States Research Site Philadelphia Pennsylvania
United States Research Site Piscataway New Jersey
United States Research Site Raleigh North Carolina
United States Research Site Redlands California
United States Research Site Richmond Virginia
United States Research Site Riverside California
United States Research Site Salem Oregon
United States Research Site San Antonio Texas
United States Research Site Schaumburg Illinois
United States Research Site Seattle Washington
United States Research Site Sherman Oaks California
United States Research Site Shreveport Louisiana
United States Research Site St. Petersburg Florida
United States Research Site Staten Island New York
United States Research Site Tampa Florida
United States Research Site Terre Haute Indiana
United States Research Site West Palm Beach Florida
United States Research Site Westminster Maryland
United States Research Site Wichita Falls Texas
United States Research Site Willoughby Ohio

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score HAM-A total score 0-56 units, 14 questions scored on scale of 0-4 (0= Not present, 4=Very severe) . Higher HAM-A scores indicate higher levels of anxiety Change : score at week 4 minus score at randomization Baseline to week 4 No
Secondary Change in Hospital Anxiety and Depression Scale for Anxiety (HADS-A) Total Score HADS-A total score 0-21 units, 0 is the best, Higher total scores indicate a higher severity of the mood or anxiety disorder Change : score at week 4 minus score at randomization Baseline to week 4 No
Secondary Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score The HAM-A psychic anxiety cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe) . Higher scores indicate higher levels of psychic anxiety disorder.
Change: score at week 4 minus score at randomization
Baseline to week 4 No
Secondary Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score The HAM-A Somatic cluster score 0-28 units consists of 7 questions scored on scale of 0-4 (0=Not present, 4=Very severe ) . Higher scores indicate higher levels of psychic anxiety disorder. Baseline to week 4 No
Secondary Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Percent Maximum Total Score Q-LES-Q total score is the sum of the first 14 times of Q-LES-Q, and this total score is converted to a % maximum total score by : Q-LES-Q total score /70 x 100%, Larger values indicate a higher perceived quality of life enjoyment and satisfaction.
Change : percentage at week 4 minus percentage at randomization
Baseline to week 4 No
See also
  Status Clinical Trial Phase
Completed NCT03535805 - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Recruiting NCT05419934 - EMDR Therapy in Young Children, a Double-blinded Randomized Controlled Trial N/A
Active, not recruiting NCT04136054 - Better Sleep in Psychiatric Care - Anxiety and Affective Disorders N/A
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT04647318 - Physiological Response to Self-compassion Versus Relaxation N/A
Active, not recruiting NCT05114824 - Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Completed NCT05078450 - Mood Lifters Online for Graduate Students and Young Professionals N/A
Not yet recruiting NCT06162624 - Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons N/A
Not yet recruiting NCT05747131 - Emotion Detectives In-Out: Feasibility and Efficacy of a Blended Version of the Unified Protocol for Children N/A
Not yet recruiting NCT05863637 - Intensive Short-Term Dynamic Psychotherapy (ISTDP) for Anxiety Diagnoses in a Primary Care Setting N/A
Not yet recruiting NCT05225701 - Efficacy of a Transdiagnostic Guided Internet-Delivered Intervention for Emotional, Trauma and Stress-Related Disorders. N/A
Completed NCT02579915 - Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC) N/A
Recruiting NCT02186366 - Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type N/A
Recruiting NCT02376959 - Effect of Spiritist "Passe" Energy Therapy in Reducing Anxiety in Volunteers N/A
Not yet recruiting NCT02126787 - Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment N/A
Completed NCT02134730 - School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3